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95% CI 1.11–1.15, p < 0.005) and grade III meningioma 
(HR:4.51, 95% CI 1.90–10.69, p < 0.005) were related with 
lower survival. Meningioma treatment had no influence on 
the survival (p > 0.05). The association between surgery and 
radiotherapy in BC treatment improved the outcome (HR 
0.37, 95% CI 0.23–0.93, p < 0.05). Grade III meningioma 
and receptor hormonal status influenced synchronous tumors 
(p < 0.05) but had no influence on metachronous tumors sur-
vival (p > 0.05) on stratified analysis. Synchronous tumors 
were associated with lower survival. Increasing age had a 
negative influence on patient survival. Although surgery and 
radiotherapy for breast cancer had a positive influence in the 
outcome, meningioma treatment was not related with sur-
vival. Grade III meningioma and hormonal receptor status 
only influenced synchronous tumors patient survival.
Keywords Meningioma · Breast cancer · Treatment · 
Survival · Epidemiology
Introduction
Meningiomas (M) are arachnoidal-cell derived tumors 
accounting for 20–30% of primary intracranial tumours [1, 
2]. According to World Health Organization (WHO) classi-
fication, most Meningiomas are grade I, with grade II lesions 
comprising 420–30% and grade III lesions 1.0 to 2.8%. They 
are more frequent in elderly patient (60–70 years) with a 
female predominance (3.5:1 female:male ratio).
Breast cancer (BC) is the most common malignancy 
in women. The incidence rate of breast cancer has been 
decreasing in the last decades (in 2011 about 130–135 per 
100,000) [1, 2] and the survival has been increasing (84 and 
89–92% 5-year progression free survival (PFS) and overall 
survival (OS) respectively) [3, 4]. The hormonal influence 
Abstract The prognosis of the association between Breast 
Cancer (BC) and Meningioma (M) is unknown. To evaluate 
the survival impact of tumor exposure sequence in patients 
with both tumors. Patients were divided in groups accord-
ing to the tumors sequence: BC before M (group 1), syn-
chronous BC + M (group 2) and BC after M (group 3). The 
SEER database was used. Demographics, meningioma and 
breast cancer variables were analyzed. The primary out-
come was oncological survival. A total of 1715 patients 
were included (median follow-up:84 months). Group 2 had 
the shortest survival (median:32 months) and group 1 the 
longest (median:110 months). On the unadjusted analysis, 
group 2 had the shortest survival (HR:3.13, 95% CI 1.62–
6.04) and adjusted analysis confirmed this finding (HR 3.11, 
95% CI 1.58–6.19), with no statistical difference between 
the metachronous tumors groups. Increasing age (HR:1.13, 
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of a higher number of breast cancer subtypes has an impact 
on treatment choices.
Schoenberg et al. in 1975 [5] described, for the first time, 
an increased incidence of meningiomas in the group of 
patients diagnosed with breast cancer. This association is 
still not clear since epidemiological studies and other reports 
show contradictory findings [5–11]. In 1979 Donnell et al. 
described the importance of estrogen receptors (ER) in men-
ingiomas. Progesterone receptors (PR) were also identified 
in meningioma cells, becoming the main hormone receptor 
recognized in those cells (70% PR versus 30% ER [12]). PR 
negative meningiomas tend to be larger and are normally 
classified as grade II or grade III. The absence of PR’s or 
ER’s expression is related with a more aggressive behavior, 
higher risk of progression and higher recurrence [13]. PR’s, 
grade and mitotic index are combined in a prognostic index 
related with patients’ outcome where absence of PR’s and 
higher grade and mitotic index are related with poorer prog-
nosis [11, 12].
When considering cytogenetic and genetic analysis, 
absence of PR’s or presence of ER’s was related with karyo-
type abnormalities, namely in chromosomes 14 and 22. [14, 
15] Genetic analysis has also supported the M-BC associa-
tion as a variation in DNA-helicase BRIP1 (BRCA1 interact-
ing protein C-terminal helicase 1) and ATM (ataxia-telangi-
ectasia mutated) gene (phosphatidylinositol-3-kinase family 
related with DNA breakdowns repair) has been related with 
both meningioma and low-risk variants of breast cancer [16, 
17]. Despite the relevance in some breast cancers, [BRCA 
(Breast Cancer) 1 and 2] mutations are not common in men-
ingiomas [14]. Therefore the clinical impact of these find-
ings has not been proven and no widely used prognostic 
score using genetic testing has been established.
Although a clinical association between meningioma 
and breast cancer has been described as well—women with 
both lesions have smaller-sized meningiomas and more 
advanced BC—[18], findings considering the impact of this 
association in patients’ survival are scarce. Therefore, our 
aim was to evaluate the survival impact of tumor exposure 
sequence—synchronous or metachronous—in patients with 
both tumors.
Materials and methods
Study population
The SEER database—SEER 18 (November 2014), 
1973–2012—of the National Institute of cancer in the United 
States of America was used to conduct a retrospective cohort 
study. This collects information on Cancer incidence and 
survival in the United States covering around 28% of the 
population. [4, 19].
Adult patients with meningioma and associated breast 
cancer were identified. All patients diagnosed with other 
tumors apart from the ones specified above were excluded.
No IRB/ethics committee approval or patient consent was 
needed to conduct this study as per SEER Dataset require-
ments. [4, 19].
Exposure
Three groups were defined: group 1—patients with menin-
gioma diagnosed after the breast cancer diagnosis (BC → 
M), group 2—patients with synchronous meningioma and 
breast cancer (M + BC) and group 3—patients where men-
ingioma preceded the diagnosis of breast cancer (M → BC). 
Group 3 was considered the reference group. The definition 
of synchronous meningioma and breast cancer was defined 
as those tumours diagnosed in the same year.
Outcome
The outcome was death attributed to one of the cancers in 
the study (meningioma or breast cancer). The survival was 
measured in months after the diagnosis of the first tumor.
Covariables
Demographic and clinical characteristics such as: age at 
diagnosis, gender, race/ethnicity, meningioma site, grade 
and associated treatment, breast cancer grade and treatment 
and breast cancer receptors (estrogen and progesterone) were 
analysed [4, 19].
Statistical analysis
Chi square test was used to compare frequency distribu-
tions of variables between patient subgroups and analysis 
of variance was used to compare the means of continuous 
variables.
The individuals with missing values in the survival time 
were excluded from the survival analysis. To explore the 
survival graphically we computed a Kaplan–Meier graph. 
In addition, we used the Cox proportional hazards mod-
els to compute hazard ratios (HR) and the 95% confidence 
intervals (CI) of the mortality risk. The proportionality of 
hazards assumption was evaluated visually and graphically 
using the Schoenfeld residuals. P values < 0.05 were consid-
ered significant. We constructed two models, one unadjusted 
and the final model adjusted for the co-variables above men-
tioned. We tested interactions between the co-variables and 
the sequence of breast cancer and meningioma. The co-
variables with positive interactions were stratified. Because 
of its importance as a possible effect modifier we tested an 
age interaction in the linear, quadratic, and cubic scale. The 
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SEER*Stat Case Listing Session was used to retrieve all 
the participants that fulfilled the inclusion criteria. For the 
statistical analysis we used STATA 13.
Results
Population characteristics
Using the SEER database, 1796 patients (99,8% women) 
with both meningioma and breast cancer were analyzed, 82 
(4.6%) were excluded from the survival analysis due to miss-
ing data regarding the follow-up. Group 1 (BC→M) was the 
group with a higher number of patients (64.5%) followed 
by group 3 (M → BC)—20.9%—and group 2 (M + BC)—
14.6%. The mean age at diagnosis (considering the first 
tumour diagnosis) was higher in group 2 (65.9 (13.2) years, 
p < 0.001). White patients presented with a higher number 
of cases in all three groups. The mean time from the first 
tumor to the second was 7.6 years in group 1 (BC → M) and 
2.9 years in group 3 [data not shown in tables].
The clinic and pathologic features analyzed for men-
ingioma were the site, grade and treatment. In all groups 
the most common location was the cerebral meningioma 
(group 1(BC → M): 84.9%; group 2 (M + BC): 86.6%; group 
3 (M → BC): 85.9%) and in all groups the non-treatment 
approach was the most common (group 1(BC→M):59%; 
group 2(BC + M): 74,4%; group 3(M → BC):46.8%). The 
majority of patients submitted to surgery were in group 3 
(M → BC)—44.4% versus 33.2% in group 1 (BC → M) and 
21.4% in group 2 (BC + M). Group 2 (M + BC) was the one 
with less patients submitted to radiotherapy [4.2% versus 
7.8% in group 1 (BC→M) and 8.8% in group 3 (M → BC)] 
(p value < 0.001). In the majority of the cases, the grade of 
the meningioma was not specified (as no surgical resection 
or biopsy were addressed and therefore no specimen was 
obtained).
Regarding breast cancer clinicopathologic characteris-
tics, in all groups, the most common grade of breast cancer 
was “moderately differentiated” (group 1(BC → M): 35.4%; 
group 2(BC + M): 38.2%; group 3(M → BC): 39.9%) fol-
lowed by “poorly differentiated” (group 1(BC → M): 27.2%, 
group 2(BC + M): 34.4%; group 3(M → BC): 30.6%). Con-
sidering breast cancer stage, group 2 (BC + M) had the 
higher prevalence of “regional” [36.3% versus 25.6% in 
group 1 (BC → M) and 27.1% in group 3(M→BC)] and 
“distant” (19.8 versus 3.1% in group 1 and 4.0% in group 
3) tumors. On the other hand, group 1 (BC → M) had the 
higher prevalence of “in situ and localized” tumors (71.2% 
versus 68.9% in group 3 (M → BC) and 43.9% in group 2 
(BC + M): (p value < 0.001)]. “Surgery and radiotherapy” 
was the main treatment option in all groups (group 1 (BC → 
M)—49.9%, group 2 (BC + M)—45.0% and group 3 (M → 
BC)—64.5%) while “surgery” alone was more prevalent in 
group 1 (BC → M) [49.8 versus 38.2% in group 2 (BC + M) 
and 15.7% in group 3(M → BC)] and “no treatment” had a 
higher prevalence in group 2 (BC + M) [14.5 versus 3.0% 
in group 1 (BC → M) and 8.4% in group 3(M → BC)] (p 
value < 0.001). Concerning breast cancer hormonal receptor 
status, both receptors were positive in 64.4% of group 3(M 
→ BC), 59.2% of group 2 (BC + M) and 46.7% in group 1 
(BC → M) patients (p value < 0.001) (Table 1).
Survival analysis
The study population of 1715 participants was followed for 
176.437 person/month, with a total of 172 deaths. Group 
1 (BC→M) had the largest number of deaths—136 (death 
attributed to breast cancer or meningioma). Both groups 2 
(BC + M) and 3 (M→BC) had 18 deaths each; 154 deaths 
were attributed to breast cancer and 18 to meningioma. The 
median overall survival in months after the diagnosis of the 
first tumor was lower in group 2 (BC + M), with 32 months, 
and higher in group 3 (M → BC), with 66 months, and group 
1 (BC → M) 110 months (Logrank Test p < 0.001).
The unadjusted survival analysis showed that between 
group 1 (BC → M) and group 3 (M → BC), there was no 
statistical difference in the hazard risk of death (group 3 (M 
→ BC) HR 0.87; 95% CI 0.52–1.46, p:0.56), opposite to 
what was identified in group 2 (BC + M) (HR 3.13, 95% CI 
1.62–6.04, p < 0.001) (Table 2).
The characteristics described in the literature particularly 
associated with meningioma that showed to have influence 
in the increase of risk of death in the adjusted analysis 
were: age at diagnosis of the first tumor (HR 1.13, 95% CI 
1.11–1.15, p < 0.005) and meningioma grade III (HR 4.51, 
95% CI 1.90–10.69, p < 0.005).
When considering the hormonal receptor status in the 
breast cancer specimens, the presence of both estrogen and 
progesterone receptors influence survival increasing the 
risk of death (HR 1.73, 95% CI 1.18–2.85, p < 0.05), when 
compared with “both receptors negative” (reference group) 
and “one receptor positive” (HR 1.46, 95% CI 0.87–2.44, 
p > 0.05) (Table 3).
When stratifying for meningioma grade, in the first group 
of grade I, II and unknown (grouped together due to the 
insufficient number of deaths to analyze the categories sepa-
rately) only the synchronous cancers posed a risk for mor-
tality (HR 3.13, 95% CI 1.62–6.04, p < 0.001). In the grade 
III meningioma, only the synchronous cancers posed a risk 
for mortality but with a very high HR (HR 80.6, 95% CI 
5.25–1236.9, p < 0.001) (Table 4).
When stratifying for breast cancer hormonal recep-
tor status, only the synchronous cancers have a signifi-
cant HR. An increased risk of death is noted in BC + M 
group when at least one of the tested hormonal receptor is 
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Table 1  Baseline characteristics of the patients with meningioma and meningioma and breast cancer at any time
NOS no other specification, ER estrogen receptor, PR progesterone receptor
BC → Meningioma—Meningioma was diagnosed after the Breast cancer diagnosis, BC + Meningioma—meningioma and breast cancer are syn-
chronous cancers, Meningioma → BC—Meningioma preceeds the diagnosis of breast cancer
Meningioma and breast cancer at any time Overall
BC → Meningioma
N (%)
BC + Meningioma
N (%)
Meningioma → BC
N (%)
p value
Total n (%) 1158 (64.5) 262 (14.6) 376 (20.9) 1796
Age at the diagnosis (years) 62.1 (12.4) 65.9 (13.2) 64.2 (12.6) < 0.001 67.98
Sex
 Female (%) 1154 (99.7) 262 (100) 376 (100) > 0.05 1792
Race
 White 967 (83.5) 213 (81.3) 306 (81.4) > 0.05 1486
 Black 96 (8.3) 30 (11.4) 43 (11.4) 169
 Other 95 (8.2) 18 (6.9) 27 (7.2) 140
 Unknown 0 1 (0.4) 0 1
Site of the meningioma
 Cerebral meningioma 984 (85.0) 227 (86.6) 323 (85.9) > 0.05 1534
 Spinal meningioma 49 (4.2) 11 (4.2) 20 (5.3) 80
 Meningioma NOS 125 (10.8) 24 (9.2) 33 (8.8) 182
Grade meningioma
 I 133 (11.5) 27 (10.3) 60 (16.0) > 0.05 220
 II 35 (3.0) 4 (1.5) 8 (2.1) 47
 III 27 (2.3) 3 (1.2) 12 (3.2) 42
 Unknown 963 (83.2) 228 (87) 296 (78.7) 1487
Meningioma treatment
 Surgery 385 (33.2) 56 (21.4) 167 (44.4) < 0.001 608
 Radiotherapy 90 (7.8) 11 (4.2) 33 (8.8) 134
 None 683 (59.0) 195 (74.4) 176 (46.8) 1054
Breast cancer grade
 Well differentiated 178 (15.4) 44 (16.8) 78 (20.8) < 0.001 300
 Moderately differentiated 413 (35.7) 100 (38.2) 150 (39.9) 663
 Poorly differentiated 318 (27.5) 90 (34.4) 115 (30.6) 523
 Undifferentiated 31 (2.7) 4 (1.5) 5 (1.3) 40
 Unknown 218 (18.7) 24 (9.1) 28 (7.4) 270
Breast cancer stage
 In situ and localized 825 (71.2) 115 (43.9) 259 (68.9) < 0.001 1199
 Regional 297 (25.6) 95 (36.3) 102 (27.1) 494
 Distant 36 (3.1) 52 (19.8) 15 (4.0) 103
Breast cancer treatment
 Surgery 577 (49.8) 100 (38.2) 182 (15.7) < 0.001 859
 Radiotherapy 8 (0.7) 6 (2.3) 3 (1.1) 17
 Surgery and radiotherapy 538 (49.9) 118 (45.0) 169 (64.5) 825
 No treatment 35 (3.0) 38 (14.5) 22 (8.4) 95
Breast cancer receptors (ER and PR)
 Both negative 449 (38.8) 63 (24.0) 86 (22.8) < 0.001 598
 One receptor positive 168 (14.5) 44 (16.8) 48 (12.8) 260
 Both positive 541 (46.7) 155 (59.2) 242 (64.4) 938
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positive—ER+/PR- or ER-/PR + or ER+/PR+ (both recep-
tors negative: HR 4.10, 95% CI 1.62–6.04, p < 0.001 and at 
least one receptor positive: HR 80.6, 95% CI 5.25–1236.9, 
p < 0.001) (Table 5).
Discussion
The previous literature has focused on epidemiological rela-
tion and biological risk factors between breast cancer and 
Table 2  Hazard ratios for 
death of breast cancer and/
or meningioma—unadjusted 
analysis
BC → Meningioma—Meningioma was diagnosed after the Breast cancer diagnosis, BC + Meningioma—
Meningioma and breast cancer are synchronous cancers, Meningioma → BC—Meningioma preceeds the 
diagnosis of breast cancer
No of subjects Hazard ratio p value (95% CI)
Variable 1715
Death by meningioma and breast cancer
 Unadjusted
  Meningioma → BC 1 (Ref.)
  BC + Meningioma 3.13 0.001 (1.62–6.04)
  BC → Meningioma 0.87 0.56 (0.52–1.46)
Table 3  Hazard ratios for 
death of breast cancer and/or 
meningioma—Adjusted analysis
BC → Meningioma—Meningioma was diagnosed after the Breast cancer diagnosis, BC + Meningioma—
Meningioma and breast cancer are synchronous cancers, Meningioma → BC—Meningioma preceeds the 
diagnosis of breast cancer
No of subjects Hazard ratio p value (95% CI)
Variable 1715
Death by meningioma or breast cancer
 Meningioma → BC 1 (Ref.)
 BC + Meningioma 3.13 0.001 (1.58–6.19)
 BC → Meningioma 1.01 > 0.05 (0.65–1.90)
Age at diagnosis (year) 1.13 < 0.001 (1.11–1.15)
Grade of meningioma
 I 1 (Ref.)
 II 1.48 > 0.05 (0.41–5.35)
 III 4.51 0.001 (1.90-10.69)
 Unknown 1.12 > 0.05 (0.55–2.26)
Treatment of meningioma
 None 1 (Ref.)
 Surgery 0.99 > 0.05 (0.62–1.56)
 Radiotherapy 0.90 > 0.05 (0.43–1.87)
Breast cancer stage
 In situ and localized 1 (Ref.)
 Regional 1.14 > 0.05 (0.81–1.62)
 Distant 0.27 > 0.05 (0.04–1.98)
Treatment of breast cancer
 No treatment 1 (Ref.)
 Surgery or radiotherapy 0.57 > 0.05 (0.29–1.14)
 Surgery and radiotherapy 0.37 < 0.05 (0.23–0.93)
Breast cancer receptors (ER and PR)
 Both negative 1 (Ref.)
 One receptor positive 1.46 > 0.05 (0.87–2.44)
 Both positive 1.73 < 0.05 (1.18–2.85)
168 J Neurooncol (2018) 136:163–171
1 3
meningioma—Milano and Grossman [18] first described 
the clinicopathologic characteristics in the SEER cohort, 
but little is known about the true impact of these tumors 
in terms of patients’ oncological prognosis. In this context, 
the present study shows that synchronous breast cancer and 
meningioma (BC + M) is associated with a worst prognosis 
when compared to both breast cancer followed by meningi-
oma (BC→M) and meningioma followed by breast cancer 
(M → BC)—metachronous tumors.
When considering both BC + M and BC → M, the first 
group has a statistically significant worst unadjusted sur-
vival (HR 3.13, 95% CI 1.62–6.04; Logrank Test p < 0.001) 
(Table 3).
So far, the literature has sustained the relation between 
breast cancer and meningioma is due to common risk factors 
such as gender, age, hormone exposure (endogenous or 
exogenous), and some epidemiological variants [10]. The 
majority of these studies are based on national oncological 
databases and share the limitation of controlling for con-
founding [20]. Therefore, an adjusted analysis for survival 
was performed considering age at diagnosis, meningioma 
grade, breast cancer receptors, treatment of meningioma and 
treatment of breast cancer.
Increased age at diagnosis (HR 1.13, 95% CI 1.11–1.15) 
was related with worst prognosis (Table 3). Among elderly, 
most breast cancers are hormone-responsive [21] and men-
ingiomas are benign in this gender. However, the decreased 
tolerance to treatment side effects and overall physiologic 
reserve often result in under treatment and higher mortality 
in this subgroup of patients [20].
Table 4  Hazard ratios for 
death of breast cancer and/or 
meningioma, stratified by grade 
meningioma (unadjusted)
BC → Meningioma—Meningioma was diagnosed after the Breast cancer diagnosis, BC + Meningioma—
Meningioma and breast cancer are synchronous cancers, Meningioma → BC—Meningioma preceeds the 
diagnosis of breast cancer
No of subjects Hazard ratio p value (95% CI)
Variable 1715
Death by breast cancer and meningioma
 Meningioma grade I, II and unknown
  Meningioma → BC 1 (Ref.)
  BC + Meningioma 3.13 0.001 (1.62–6.04)
  BC → Meningioma 0.87 0.56 (0.52–1.46)
 Meningioma grade III
  Meningioma→ BC 1 (Ref.)
  BC + Meningioma 80.6 0.001 (5.25–1236.9)
  BC → Meningioma 2.61 > 0.05 (0.52–12.95)
Table 5  Hazard ratios for 
death of breast cancer and/or 
meningioma, stratified by breast 
cancer receptor (unadjusted)
BC → Meningioma—Meningioma was diagnosed after the Breast cancer diagnosis, BC + Meningioma—
Meningioma and breast cancer are synchronous cancers, Meningioma → BC—Meningioma preceeds the 
diagnosis of breast cancer
No of subjects Hazard ratio p value (95% CI)
Variable 1715
Death by breast cancer and meningioma
 ER and PR receptors negative
  Meningioma → BC 1 (Ref.)
  BC + Meningioma 4.10 0.001 (1.62–6.04)
  BC → Meningioma 0.55 0.56 (0.52–1.46)
 ER or PR receptors positive
  Meningioma→ BC 1 (Ref.)
  BC + Meningioma 80.6 0.001 (5.25–1236.9)
  BC → Meningioma 2.61 > 0.05 (0.52–12.95)
 ER and PR receptors positive
  Meningioma→ BC 1 (Ref.)
  BC + Meningioma 80.6 0.001 (5.25–1236.9)
  BC → Meningioma 2.61 > 0.05 (0.52–12.95)
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Grade III meningioma was a risk factor for lower sur-
vival (HR 4.51, 95% CI [1.90–10.69) (Table 4). In the lit-
erature, high recurrence and mortality rates (75 and 90% 
respectively in 5 years) are reported [22], which support the 
present results.
The biology of breast cancer cells was evaluated in terms 
of ER and PR receptors status. ER+/PR+ receptor status was 
related with a worse outcome (HR 1.73, 95%CI 1.18–2.85, 
p < 0.05) (Table 3). This was an unexpected result as the 
literature supports a better outcome in patients with ER 
positive breast cancer tumors and also because PR positive 
tumors are responsive to anti-hormonal treatment [23]. But 
the lack of information on the HER-2 receptors and details 
on the breast cancer stage does not allow any conclusions 
in this regard.
The treatment approach of meningiomas had no impact 
in overall survival (p > 0.05). On the other hand, when con-
sidering breast cancer treatment (“no treatment” as refer-
ence group), “surgery and radiotherapy” was related to a 
better survival (HR 0.37, 95% CI 0.23–0.93) but “surgery 
or radiotherapy” alone did not influence the outcome (HR 
0.57, 95% CI 0.29–1.14) although no information concern-
ing chemotherapy is available in this database. These results 
highlight a better outcome for a more aggressive oncological 
approach in breast cancer patients. These findings support 
the breast cancer treatment as one of the main prognostic 
factors in these patients, which was expected considering 
the overall higher aggressiveness of this tumor.
The adjusted analysis confirmed the previous results of 
unadjusted analysis for worst outcome of BC + M group (HR 
4.10, 95% CI 1.62–6.04). (Table 3) One possible explana-
tion for this finding is the expected morbility and mortality 
related with both tumors treatment and prognosis. This may 
reduce life expectancy in this group, as its effects are pre-
sent for both tumors from the beginning of the exposure. On 
the other hand, in BC → M group the mean time between 
the tumors is 7.6 years where patient had been exposed to 
only one tumor and its effects. Nevertheless, only 18 death 
events where related with meningioma in the whole studied 
population, 2 in BC + M Group. Therefore, we can consider 
that the mortality due to meningioma was not responsible 
for this difference and hypothesize about a possible biologi-
cal difference between both BC + M and BC → M groups. 
Indeed, BC + M had the higher prevalence of “poorly dif-
ferentiated” (34.4%) breast cancer grade, “regional” (36.3%) 
and “distant” (19.8%) breast cancer stage and”no treatment” 
approach either in meningioma (74.4%) and in breast can-
cer (14.5%). Unfortunately, in a significant amount of cases 
(1487 of meningiomas and 270 of breast cancer tumors out 
of 1796) the tumor grade is unknown, which does not allow 
further conclusions (Table 1). These results may support the 
fact that BC characteristics are different among these groups 
with a trend toward a greater aggressiveness in synchronous 
tumors. In fact, a possible interaction between both tumors 
is supported by the fact that both meningioma and breast 
cancer are able to produce peptides released in circulation 
with known promoter oncogenic role [24].
In this study, we looked for the influence in oncological 
survival of the biology and histology of meningioma and 
breast cancer in each group. The stratification of the study 
sample according to meningioma grade revealed no influ-
ence in BC → M group but only in BC + M group. (Table 4) 
On the other hand, when we considered the stratification 
according to hormonal receptor status, a negative influence 
in the outcome was observed in the BC + M group with no 
influence in the BC → M group (Table 5). These findings 
may provide an indirect support of an increased interaction 
and aggressiveness of synchronous tumors, as the oncologi-
cal survival is dependent of meningioma grade- even though 
the missing data raises concerns about the power of this 
covariate analysis and the true impact of the meningioma 
grade in survival—and breast cancer biology, which does 
not happen in metachronous tumors. Nevertheless, hormonal 
receptor positivity is usually related with longer survival 
rates [25]. For unknown reasons, this was a paradoxal effect 
in this study.
Our results support for the first time the sequence of 
exposure as an important factor of prognosis in patients 
with both tumors. Even though dual-cancer patients outside 
of known syndromic or familial clinical situations are quite 
uncommon, a coherent statistical analysis was performed 
according to the dimension of study population.
Nevertheless, some limitations are noted. The used defini-
tion of synchronous tumors as tumors diagnosed in the same 
year may be questioned. However, this was the possible 
approach according to the provided year of diagnosis in the 
database. It should also be noted that the higher frequency 
of imaging exams performed during breast cancer staging 
procedures, may also be responsible for a higher number of 
diagnoses of synchronous tumors. However, this effect exists 
in all the 3 subgroups, as the follow-up for both malignances 
implies increased number of imaging exams. The diagnostic 
definition of meningiomas can also be questioned as 1188 
cases have no histology to document (1054 of cases has no 
treatment and 134 had only radiotherapy) and the similar 
rate of grade II and III meningiomas doesn’t find its paral-
lel in the remaining literature which may highlight different 
diagnostic criteria along the recruitment time (1973–2012) 
and the need of a central review of the histological diagno-
sis. Nevertheless, magnetic resonance imaging has accurate 
methods to provide a proper diagnosis of meningioma in 
the majority of the cases (sensivity 83.3%, specificity 100% 
and accuracy 93.3%) [25]. Considering the majority of cases 
were collected in the last years (despite the database started 
in 1973), the diagnostic assumptions are valid for this study 
purposes. Finally, a concern towards residual confounding 
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in this retrospective study exists as the adjustment for all 
the risk factors mentioned in the literature was not feasible. 
In this sense, we would like to point that no reliable infor-
mation was found in database concerning chemotherapy. 
Indeed, this is not a major issue for meningiomas as the 
use of chemotherapy is residual. Nevertheless, it is one of 
the mainstays of therapy for disseminated breast cancer that 
should be considered in future studies.
Despite these limitations, this study provides an adjusted 
survival analysis for consensual risk factors in patients with 
both breast cancer and meningioma. In future studies, treat-
ment-related morbidity should be considered and hormonal 
receptors should be evaluated not only for breast cancer but 
also for meningioma. New treatment approaches should be 
tested for different tumor exposure sequences, as this study 
suggests this as an important factor for oncological survival.
Conclusion
In this study, synchronous breast cancer and meningioma 
had shorter survival when compared with metachronous 
tumors, either in unadjusted or adjusted analysis. Increas-
ing age and grade III meningioma were related with lower 
survival rates. Concerning the treatment approach to breast 
cancer, both surgery and radiotherapy were related to a bet-
ter survival, whereas in meningioma treatment no particular 
approach proved to be superior when compared with the 
others. Meningioma grade and hormonal receptor status 
influenced only synchronous tumors (grade III and hormo-
nal receptor positivity related with lower survival rates). A 
better understanding of this group of patients can provide 
valuable information for clinicians in order to provide a tai-
lored clinical approach.
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